-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicara Therapeutics Q3 net loss widens 96% to $71.2 million

PUBT·11/09/2026 13:59:22
Listen to the news
Bicara Therapeutics Q3 net loss widens 96% to $71.2 million
  • Bicara Therapeutics’ third-quarter 2026 net loss widened 96% year over year to $71.2 million.
  • R&D expenses rose 71% to $56.5 million, while general and administrative expenses more than doubled to $19.2 million.
  • Substantial enrollment in the FORTIFI-HN01 pivotal trial enables a topline interim analysis in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.